Clinical trial
Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian…
NCT00010179 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00010179 |
|---|---|
| Title | Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer |
| Official title | Randomized Phase II Study Of NX 211 Given By Two Different Intravenous Schedules In Advanced And/Or Recurrent Epithelial Ovarian Cancer |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer |
| Intervention type | Drug |
| Interventions | lurtotecan liposome |
| Enrollment | 81 |
| Start date | Oct 31, 2000 |
| Primary completion | Oct 22, 2002 |
| Completion | Sep 22, 2008 |
| First posted | Feb 26, 2004 |
| Last update posted | Apr 6, 2020 |
| Countries | Canada, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: